Skip to content
Research Article Open access CC BY 4.0

Severe Pulmonary Arterial Hypertension Induced by Dasatinib in a Patient with Chronic Myeloid Leukemia: A Case Report

Siyam Hamady, BOUCETTA Abdullah, OBEIDAT Saleh, Miryem HABOUB, Rachida HABALL

Cardiology and Angiology: An International Journal · pp. 39–44 · Published 20 Aug 2025

10.9734/ca/2025/v14i3497

Abstract

Pulmonary arterial hypertension (PAH) is a rare but recognized adverse effect of tyrosine kinase inhibitors, notably Dasatinib, prescribed in chronic myeloid leukemia (CML). Due to potential reversibility, prompt recognition and management are essential. We report a 60-year-old male receiving Dasatinib for CML who presented with NYHA class IV dyspnea. Echocardiography showed severe right ventricular dilation and elevated pulmonary pressures. Right heart catheterization confirmed precapillary PAH. Other causes were ruled out. Following discontinuation of Dasatinib and initiation of combination PAH-specific therapy (epoprostenol, bosentan, tadalafil), the patient demonstrated clinical and hemodynamic improvement. This case highlights the need for vigilance in patients on Dasatinib, especially when respiratory symptoms arise. Early intervention can improve outcomes in drug-induced PAH.

Pulmonary arterial hypertension dasatinib chronic myeloid leukemia tyrosine kinase inhibitors right heart catheterization

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.